Rifat Pamukcu, MD

Dr. Rifat Pamukcu was a Founder, Director and CSO of Cell Pathways, Inc.(CPI), an emerging pharmaceutical company acquired by OSI Pharmaceuticals. He directed the basic science, preclinical drug development, clinical research, regulatory programs, and various aspects of chemical scale-up and manufacturing over the course of decade. While at CPI, he led the development of exisulind, an oral apoptosis modulator and phosphodiesterase inhibitor, for the treatment of Familial Adenomatous Polyposis (FAP). He received his BA in Biology from The Johns Hopkins University and his MD degree from the University of Wisconsin School of Medicine. Dr. Pamukcu has authored over 110 journal articles, book chapters, and abstracts and is an inventor on over 280 issued or pending patents in the areas of drug discovery and development for cancer prevention, cancer treatment, and inflammatory bowel disease.